{"filings":[{"id":1941522,"accession_number":"0001193125-26-323841","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-07-29T20:30:15+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q2 2026 net revenue $42.2M (-42% YoY); operating loss narrows to $12.0M; cash grows to $314.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $42.2M, down 42% YoY due to absence of $25M Recordati upfront payment and generic pressure on U.S. VASCEPA pricing.","Operating expenses fell 59% to $27.0M; excluding restructuring, down 38% YoY, completing $70M annual cost savings initiative.","Operating loss improved to $12.0M from $16.0M; net loss $7.7M vs $14.1M; cash grew to $314.6M, debt-free.","Global in-market demand for VASCEPA/VAZKEPA rose 59% YoY; U.S. IPE market share increased to 48% from 43%.","Company expects continued international growth, consistent U.S. volumes, and ~10% cash growth by year-end 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":451836,"accession_number":"0001193125-26-224771","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-05-15T01:30:16+00:00","items":["5.07"],"status":"ready","headline":"Amarin shareholders reject four proposals at AGM, limiting equity grants and forcing cash compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issuance Proposal (authority to issue shares up to £37.75M) failed with 75M for, 96M against.","2020 Stock Incentive Plan amendment to add 15M ordinary shares failed with 71M for, 95M against.","Pre-emption Proposal and Amended Articles Proposal also failed; Say-on-Pay passed but 81M votes against.","Board expects future incentive compensation to be cash-only due to inability to grant equity; cash position impacted.","Company will continue paper delivery of proxy materials, incurring needless printing and mailing costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99578,"accession_number":"0001193125-26-188935","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q1 total revenue up 7% to $45.1M; operating loss narrows 32%; cash flow positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $45.1M (+7% YoY); U.S. product revenue $35.6M flat; European revenue $4.9M (-9%); ROW $2.8M.","Operating loss narrowed to $11.3M from $16.8M; net loss $10.5M ($0.03 EPS) vs $15.7M ($0.04 EPS).","Cash and investments $307.8M; debt-free; second consecutive quarter of positive cash flow.","Reaffirms full-year 2026 positive cash flow; targeting ~$70M cost savings; restructuring charges $39.6M cumulative.","Recordati launched VAZKEPA in 10 European countries; U.S. VAZCEPA branded Rx up 17% YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":45132000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115661,"accession_number":"0001193125-26-129334","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin board shrinks from 9 to 7; directors Cohen, O'Connor resign; new compensation policy","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Directors Paul Cohen and Oliver O'Connor will not stand for re-election; resign effective before 2026 annual meeting.","Board size reduced from nine to seven members effective at the same time.","New director compensation policy: annual retainers ($62.5k or $95k for chair); equity awards of $262.5k (initial) and $175k (annual).","Equity grants conditional on shareholder approval of issuance and pre-emption proposals at the 2026 meeting; otherwise cash alternatives considered.","Directors will receive a $175,000 restricted cash award for 2025 meeting equity in lieu of prior year grant."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115660,"accession_number":"0001193125-26-068511","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q4 net loss narrows to $1.2M; revenue down 21% but cash up and positive cash flow expected in FY26","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net loss improved 97% to $(1.2)M ($0.00 per share) from $(48.6)M in Q4 2024.","Total net revenue $49.2M, down 21% YoY on U.S. price decline and prior-year ROW stocking order.","Operating loss narrowed 88% to $6.3M; restructuring delivered $31M of expected $70M savings.","Cash and investments $302.6M, up $8.4M YoY and $16M sequentially; debt-free.","Management expects positive full-year cash flow in 2026, ahead of schedule."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":213646000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115659,"accession_number":"0001193125-26-006992","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin achieves positive cash flow in Q4 2025 ahead of schedule; FY revenue $212-217M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Year-end cash $303M, up $16M from Q3; no debt; Q4 positive cash flow achieved earlier than forecast.","Q4 2025 net revenue expected $48-53M; FY 2025 net revenue $212-217M.","Restructuring: 50% of $70M OPEX savings realized; full benefit on track by June 30, 2026. Estimated restructuring costs raised to $37-40M.","VASCEPA >50% IPE prescription share in US; Recordati now managing European commercialization in most launched countries.","Two new regulatory approvals (South Korea and Singapore); >10 abstracts and >20 manuscripts published in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":213646000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132091,"accession_number":"0001193125-25-254620","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q3 net revenue $49.7M (+17% YoY), operating loss narrows 56% to $11.1M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $49.7M, up 17% YoY, driven by US sales rebound and exclusive PBM status.","Operating loss of $11.1M improved from $25.2M; SG&A down 47% to $19.7M after restructuring.","Completed transition to fully partnered commercial model (Recordati in Europe); targeting positive free cash flow in 2026.","US product revenue $40.9M (+34% YoY); Europe $4.1M (-5%); Rest-of-World $3.6M (-48%).","Net loss $7.7M ($0.02 EPS) vs $25.1M ($0.06 EPS) last year; cash $286.6M, debt-free."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":164427000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132090,"accession_number":"0001193125-25-246973","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-10-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin promotes David Keenan to EVP, COO effective October 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David Keenan, previously EVP Technical Operations and President of Europe, appointed COO effective Oct 17, 2025.","Dr. Keenan joined Amarin in May 2022 as SVP Technical Operations; promoted to EVP in July 2023.","No change to compensation as a result of the COO appointment; no family relationships or arrangements.","Keenan brings over 30 years leadership in biopharma; holds PhD in Organic Chemistry and MBA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148668,"accession_number":"0000950170-25-099878","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q2 net loss $14.1M; signs European licensing deal with Recordati, plans restructuring","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 net loss of $14.1M ($0.03 per share) vs. $1.5M net income in Q2 2024.","Total net revenue $72.7M (+8% YoY); licensing revenue up 31% on Recordati upfront.","Signed exclusive European licensing agreement with Recordati for VAZKEPA in 59 countries.","Global restructuring expected to deliver $70M in operating expense savings over 12 months.","Cash $298.7M, debt-free; U.S. product revenue down 17% to $36.5M, Europe up 85% to $6.6M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":114757000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148667,"accession_number":"0000950170-25-093444","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K/A","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amarin appoints Michael Torok to board; cash award replaces equity due to shareholder pre-emption issue","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Torok appointed non-employee director effective April 4, 2025; joins Remuneration Committee July 1, 2025.","Restricted cash award of $175,000 in lieu of annual equity award, vesting at 2026 Annual Meeting.","Conditional initial equity award of $262,500 (75% options, 25% RSUs) if shareholders approve pre-emption waiver at 2026 meeting; vests over three years.","If board service ends before equity grant, vested portion settled in cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167536,"accession_number":"0000950170-25-089218","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["1.01","2.05","7.01","9.01"],"status":"ready","headline":"Amarin licenses VAZKEPA to Recordati in Europe; launches restructuring targeting $70M annual savings","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $25M and up to $150M in milestone payments; Recordati to commercialize VAZKEPA in 59 European countries.","Global restructuring to cut operating costs by ~$70M annually; expects $30-37M in restructuring charges in Q2 2025.","Company retains U.S. rights; nearly $300M cash on hand, no debt; accelerated path to positive cash flow.","Agreement term 15 years, auto-renewal subject to commercialization in at least one country."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167535,"accession_number":"0000950170-25-072817","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Amarin shareholders reject proposal to allow share allotment without pre-emption rights at AGM","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Special resolution to allot 10% of shares without pre-emption rights failed (89.8M for, 36.0M against; needed 75%).","Board must now seek opt-out for each share issuance, described as time-consuming, expensive and subject to rejection.","Non-employee directors likely to receive supplemental cash compensation in lieu of equity at previously approved value, impacting cash.","All other 12 proposals, including director re-elections and say-on-pay, were approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167534,"accession_number":"0000950170-25-064980","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q1 2025 net revenue $42M (-26% YoY); net loss $15.7M, wider than prior year","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $42.0M vs $56.5M in Q1 2024, down 26% due to generic competition in U.S.","U.S. net product revenue $35.7M (down from $48.1M); Europe rose to $5.4M (from $1.9M).","GAAP net loss $15.7M ($0.04/sh) vs $10.0M ($0.02/sh) in Q1 2024; adjusted net loss $9.4M ($0.02/sh).","Cash & investments $281.8M at March 31, 2025, vs $308.2M a year earlier.","Regained Nasdaq compliance after 1-for-20 ADS ratio change effective April 11, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":42017000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167533,"accession_number":"0000950170-25-060165","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Amarin regains Nasdaq minimum bid price compliance after ADS ratio change","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Received Nasdaq confirmation on April 29, 2025 that bid price averaged ≥$1.00 over 10 consecutive days.","Compliance achieved after adjusting ADS-to-ordinary share ratio from 1:1 to 1:20 on April 11, 2025.","Company now fully compliant with all Nasdaq listing standards; delisting matter closed.","CEO Aaron Berg states focus remains on maximizing global value of VASCEPA/VAZKEPA.","AMRN will continue trading on the Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167532,"accession_number":"0000950170-25-052307","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-04-09T23:59:59+00:00","items":["3.03","7.01","9.01"],"status":"ready","headline":"Amarin confirms 1-for-20 ADS reverse split effective April 11 to meet Nasdaq $1 minimum bid","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADS ratio changes from 1:1 to 1:20 effective April 11, 2025, to meet Nasdaq $1.00 minimum bid price.","No assurance that post-split ADS price will equal or exceed 20x pre-split price.","Certificated ADS holders must surrender; DRS/DTC holders automatic exchange. No fractional ADSs issued.","Fractional entitlements sold; net cash proceeds distributed to holders by depositary bank.","Ordinary shares unchanged; trading symbol remains AMRN."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167531,"accession_number":"0000950170-25-051353","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-04-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin appoints Michael Torok (JEC Capital Partners) to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Torok appointed to Amarin board effective April 4, 2025.","Torok is Co-Founder and Managing Director of investment firm JEC Capital Partners.","He will stand for election at the 2025 annual general meeting.","Torok has not been assigned to any board committees initially.","He will receive standard non-employee director compensation per company policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184827,"accession_number":"0000950170-25-046873","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Mark DiPaolo to step down at Amarin's May 2025 annual meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mark DiPaolo will not stand for re-election and leaves the Board after the 2025 Annual Meeting expected in May.","Departure is not due to any disagreement with the company on operations, policies, or practices.","DiPaolo's board service ends at the meeting; no replacement announced yet."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184826,"accession_number":"0000950170-25-037618","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","3.03","7.01","9.01"],"status":"ready","headline":"Amarin Q4 revenue $62.3M, net loss $48.6M; announces 1-for-20 ADS reverse split to maintain listing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 total net revenue $62.3M, down 17% YoY; net loss $48.6M vs $5.8M loss in Q4 2023.","U.S. VASCEPA revenue fell to $44.2M from $64.9M on generic competition; European revenue rose to $4.0M, RoW to $11.9M.","Cash and investments $294.2M at Dec 31, 2024, down from $320.7M a year earlier; no debt.","Announces 1-for-20 ADS reverse split effective ~April 11, 2025 to comply with Nasdaq $1 minimum bid price.","Non-GAAP adjusted net loss $8.7M ($0.02/ADS) vs adjusted loss $0.9M in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201421,"accession_number":"0000950170-24-137894","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-12-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin appoints Peter Fishman as CFO effective December 13, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Fishman previously served as Global Controller and principal financial & accounting officer since October 2024.","Annual base salary set at $400,000 with bonus potential up to 40% of base.","Fishman has nearly 20 years of finance experience; reports to CEO Aaron Berg.","He is a CPA with an MBA from Rowan University and a BA in accounting from American University."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201420,"accession_number":"0000950170-24-130263","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Amarin gets Nasdaq extension to May 19, 2025 for minimum bid price compliance; shares transfer to Capital Market","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nasdaq granted 180-day extension until May 19, 2025 to meet $1.00 minimum bid price.","ADS will transfer from Nasdaq Global Market to Capital Market effective Nov 26, 2024.","Compliance achieved if closing bid price is at least $1.00 for 10 consecutive business days.","Company considering options including a reverse stock split to remedy the deficiency.","No guarantee of regaining compliance; delisting remains a possibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201419,"accession_number":"0000950170-24-118988","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q3 net revenue $42.3M (-36% YoY); European revenue grows, U.S. declines on generic competition","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $42.3M (-36% YoY); U.S. net product revenue $30.6M (-51%) from generic competition and CVS delisting.","European net product revenue $4.3M (up from $0.8M); VAZKEPA sales grew 19% sequentially in Spain and UK.","Net loss $25.1M ($0.06/share) vs $19.3M loss ($0.05); non-GAAP adjusted net loss $20.4M ($0.05).","Cash and investments $305.7M, flat QoQ; reaffirms cash adequate for foreseeable future.","Company committed to maintaining public listing; exploring paths to resolve issue. Virtual Analyst Day Nov 14."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":166308000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201418,"accession_number":"0000950170-24-113227","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"CFO Tom Reilly resigns effective Oct 23, 2024; interim CFO named","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Tom Reilly voluntarily resigns as EVP, CFO and Head of Global HR & Finance, effective October 23, 2024, to pursue another opportunity.","Resignation not due to any disagreement with the Company on financial statements, operations, policies or practices.","Vice President, Global Controller Peter Fishman assumes interim principal financial and accounting officer duties, reporting to CEO Aaron Berg.","Fishman has served as Global Controller since Oct 2022, with nearly 20 years of experience in accounting, financial reporting, tax, and audit.","Company is assessing next steps to identify a permanent CFO successor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217427,"accession_number":"0000950170-24-088234","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q2 revenue down 16% to $67.5M; PBM drops VASCEPA coverage; new CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $67.5M (-16% YoY); net product revenue $47.5M (-27%) pressured by US generic competition.","GAAP net income $1.5M (EPS $0.00) vs net loss $17.6M in Q2 2023; non-GAAP adj. net income $5.9M.","Cash $306.7M; $50M share repurchase program approved but not commenced.","Large PBM removed VASCEPA from exclusive coverage for Commercial national formularies effective July 1, 2024.","CEO Aaron Berg appointed; China CVRR milestone $15M; new EU patent extending VAZKEPA exclusivity to 2039."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":124010000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217426,"accession_number":"0000950170-24-087391","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-07-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin appoints Aaron Berg as CEO with $700K salary, performance options for 5M shares","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Berg's base salary $700K, eligible for cash incentive compensation; agrees to buy $100K of AMRN shares.","Performance-based option to purchase 5M shares; hurdles $1.25-$10.00 share price (60-day VWAP).","Severance: 18 months base + 0.975x base lump sum (outside change of control); 3.3x base within change of control period.","Option grant expected August 1, 2024; exercise price = closing price on grant date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237281,"accession_number":"0000950170-24-068298","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Amarin CEO resigns; large PBM to drop Vascepa coverage July 1, affecting 25% of US volume","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Pat Holt resigned; Aaron Berg appointed as President & CEO effective June 4, 2024.","Holt will provide consulting services through July 3, 2024 in exchange for his base salary.","A large national PBM will exclude Vascepa from commercial national formularies effective July 1, 2024.","Affected formularies represent ~25% of aggregate US Vascepa prescription volume; Medicare Part D unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237280,"accession_number":"0000950170-24-065585","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Amarin receives Nasdaq deficiency notice over bid price below $1.00 for 30 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Amarin on May 24, 2024 that its ADS closing bid price has been below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until November 20, 2024, to regain compliance by closing at $1.00 or more for 10 consecutive business days.","Failure by November 20 could lead to a second 180-day cure period if listing is transferred to Nasdaq Capital Market.","Amarin's ADSs continue to trade on The Nasdaq Global Market under symbol AMRN; no immediate delisting effect.","Company is evaluating options but cannot assure it will regain compliance with the Bid Price Requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237279,"accession_number":"0000950170-24-050889","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q1 revenue $56.5M (-34% YoY); European in-market sales +65% QoQ; GAAP loss $0.02","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. net product revenue fell 41% YoY to $48.1M on generic price erosion; gross margin narrowed to 55% from adjusted 70% a year ago.","GAAP net loss $10.0M ($0.02/share) vs loss $16.5M ($0.04) Q1'23; non-GAAP adjusted net loss $4.7M ($0.01) vs income $7.6M ($0.02) YoY.","European in-market sales grew ~65% Q1'24 vs Q4'23, driven by Spain (+91% patients on therapy) and UK (+28%).","EPO issued new VAZKEPA patent extending IP protection in Europe until 2039; $50M share repurchase program approved, pending UK High Court OK in Q2.","Cash & investments $308.2M, stable over seven quarters; on track for $40M annual cost savings from July 2023 restructuring."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":56519000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237278,"accession_number":"0000950170-24-046290","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-04-22T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Amarin shareholders approve $50M share repurchase program and board declassification","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved two proposals enabling up to $50M share repurchase; final step is UK High Court approval, expected by end of Q2 2024.","Plan Amendment No. 3 to 2020 Stock Incentive Plan approved, increasing share reserve by 10 million ordinary shares/ADSs.","Resolutions passed: re-election of directors Holt, Sterling III, Bonfiglio; advisory say-on-pay; EY as auditor; declassified board requiring annual director elections.","Approximately 255 million shares (61% of eligible) were present and voting at the April 18, 2024 Annual General Meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":237277,"accession_number":"0000950170-24-040675","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amarin extends VAZKEPA European patent exclusivity to 2039; defends 2033 patent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EPO granted new VAZKEPA patent covering REDUCE-IT protocol/results, extending exclusivity to April 2039.","Amarin successfully defended separate VAZKEPA patent (expires June 2033) against third-party opposition at EPO.","Legacy patent exclusivity from ANCHOR study extended via SPCs until June 2035.","Regulatory exclusivity for VAZKEPA in Europe runs until March 2031, layering with patent protections.","CEO Patrick Holt says extended runway enhances commercial and growth potential for VAZKEPA in Europe."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254832,"accession_number":"0000950170-24-022635","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin reports Q4 revenue down 17% to $74.7M; GAAP net loss $5.8M; initiates $50M share repurchase","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $74.7M in Q4 2023 vs $90.2M in Q4 2022 (-17%); US net product revenue fell to $64.9M from $88.0M due to generic competition.","GAAP net loss $5.8M ($0.01 loss per share) vs net income $0.9M in prior year; non-GAAP adjusted net loss $0.9M.","Gross margin on net product revenue declined to 58% from 70% in Q4 2022.","Cash and investments $321M at year-end; reaffirmed full-year positive cash flow of $10M.","Board initiated shareholder approval process for up to $50M share repurchase program expected by end of Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":306911000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254831,"accession_number":"0000950170-24-007688","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Amarin regains Nasdaq minimum bid price compliance; listing continues","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 25, 2024 confirming regained compliance with minimum bid price rule.","Previously notified on Oct 30, 2023 of deficiency due to ADSs closing below $1.00 for 30 days.","Regained compliance by maintaining $1.00 closing bid for 10 consecutive days, achieved Jan 24.","Company now in full compliance with all applicable Nasdaq Global Market listing standards.","Matter closed; no further action required regarding this deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254830,"accession_number":"0000950170-24-003511","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2024-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amarin reports preliminary Q4 rev $72-74M, FY rev $304-306M; announces $50M buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q4 2023 total revenue $72-74M (Europe ~$1.5M, US $64-65M, RoW $7-8M).","Full-year 2023 revenue $304-306M; cash and investments $321M; positive cash flow ~$10M.","Plans $50M share repurchase subject to shareholder and UK High Court approval, expected by end Q2 2024.","European revenue grew ~65% QoQ; VAZKEPA now available in 9 markets; US IPE market share 57%.","Believes current cash and investments adequate to support operations including buyback; on track for $40M annual savings."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":306911000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272306,"accession_number":"0000950170-23-058858","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Amarin receives Nasdaq deficiency notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ADS closing bid price below $1.00 for 30 consecutive business days triggers deficiency letter.","Company has 180 days, until April 29, 2024, to regain compliance with Nasdaq Bid Price Rule.","Regain compliance if bid price closes at $1.00 or more for 10 consecutive business days.","If not compliant by deadline, company may transfer to Nasdaq Capital Market for second 180-day period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272305,"accession_number":"0000950170-23-057121","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q3 2023: Revenue $66M (-27% YoY), net loss $19.3M; cash flow +$8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $66.1M, down 27% vs Q3 2022; net loss $19.3M vs $5.1M loss a year ago; diluted EPS loss $0.05.","U.S. net product revenue $62.4M (-3% sequentially); maintained ~57% IPE market share despite generic competition.","European revenue $0.8M; early launches in UK, Spain, Netherlands with progress under new leadership.","Generated $8M positive cash flow in quarter; cash and investments $321M; on track for $40M annual savings from July restructuring.","Partner Edding launched VASCEPA in China for severe hypertriglyceridemia; submitted CVRR indication filing to NMPA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":232198000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":272304,"accession_number":"0001193125-23-267198","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amarin appoints Jonathan Provoost as EVP, Chief Legal & Compliance Officer starting Nov 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jonathan Provoost named EVP, Chief Legal & Compliance Officer; effective November 15, 2023.","Provoost has over 20 years of corporate counsel experience, most recently VP, GC & CCO at Tris Pharma.","He will lead legal and compliance strategy, including IP, litigation, and business development.","CEO Patrick Holt states Provoost's experience will support Amarin's priorities and future path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289149,"accession_number":"0000950170-23-036766","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-08-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q2 revenue $80M (-15%); net loss narrows to $17.6M; lowers 2023 opex guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total net revenue $80.2M (-15% YoY); net product revenue $65.2M (-31% YoY) due to generic competition.","GAAP net loss $17.6M ($0.04 loss per share) vs $70.0M loss ($0.18 loss) in Q2 2022; non-GAAP adjusted net income $8.6M.","Cash and investments $313M; generated positive cash flow of $9M during the quarter.","Lowering 2023 operating expense guidance to $240-250M from $270-285M; cost reduction plan savings $40M over 12 months.","Spain's drug pricing committee recommended national reimbursement of VAZKEPA; regulatory approvals in China and Saudi Arabia."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":166142000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289148,"accession_number":"0001193125-23-192541","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-07-25T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Amarin shareholders approve 20M share increase to stock plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved Amendment No. 2 to 2020 Stock Incentive Plan, increasing share reserve by 20M ordinary shares or ADSs.","Re-elected directors Oliver O'Connor, Mark DiPaolo, and Odysseas Kostas with substantial votes for.","Advisory vote approved executive compensation; board adopted 1-year frequency for future say-on-pay votes.","Ernst & Young LLP appointed as U.S. independent auditors and U.K. statutory auditors for 2023.","Board authorized to allot shares up to £125M nominal, with authority to disapply pre-emption rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289147,"accession_number":"0001193125-23-190185","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-07-20T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Amarin appoints Patrick Holt as President and CEO effective July 18, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Patrick Holt appointed President & CEO and Board member; base salary $675,000, eligible for cash incentive.","Receives performance-based option for 5,000,000 shares with share price hurdles $2.50-$15.00.","Holt agrees to purchase $300,000 of Amarin shares in open market promptly after next trading window.","Severance: 18 months' base salary plus 1.5x target bonus outside CIC; 2x salary and bonus within CIC period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":289146,"accession_number":"0001193125-23-188876","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-07-18T23:59:59+00:00","items":["2.02","2.05","5.02","7.01","9.01"],"status":"ready","headline":"Amarin reports 23% Q/Q revenue drop to $65M; cuts 30% workforce; appoints new CEO Patrick Holt","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q2 product revenue ~$65M, down from $85M Q1; cash $313M (+$9M cash flow including $5M China milestone).","Workforce reduction of ~30% expected to save ~$40M annually; ~$10M restructuring charges in Q2.","Patrick Holt appointed President & CEO effective July 18; Aaron Berg returns to EVP, President U.S.","Retention awards for Berg, Reilly, Ketchum include cash tranches in Feb 2024/2025 and options vesting Jan 2024/2025.","Restructuring charges substantially all cash for termination benefits; payments expected by Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309904,"accession_number":"0001193125-23-173981","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-06-23T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Amarin adjourns 2023 AGM to July 21 due to insufficient quorum","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["AGM convened June 21, 2023 lacked sufficient shares for a quorum under Nasdaq rules; polls not opened.","Meeting rescheduled to July 21, 2023 at 9:00 a.m. local time; record date remains May 8, 2023.","ADS proxy instructions due to Citibank by 10:00 a.m. NY time July 17; ordinary share proxies due July 19.","No changes to proposals; shareholders who already voted need not take action unless changing vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309903,"accession_number":"0000950170-23-016878","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-05-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q1 revenue $86M (-9% YoY); lowers FY2023 opex guidance to $270-285M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["U.S. net product revenue $82.3M (-7% QoQ); generic competition impacts volume and price.","GAAP net loss $16.5M ($0.04 loss per share) vs loss $31.6M YoY; adjusted net income $7.6M.","Gross margin 55% (70% excluding $12.3M supplier amendment charge) vs 76% prior year.","Lowered 2023 operating expense guidance to $270-285M from $290-305M; cash $304.9M.","Europe early launch VAZKEPA in UK, Sweden, Finland; CSL Seqirus partnership for Australia/NZ."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":85975000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":309902,"accession_number":"0000950170-23-012983","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-04-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Amarin appoints Aaron Berg as Interim CEO and adds Oliver O'Connor to Board, effective April 17, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aaron Berg, EVP President-U.S., named Interim CEO and President; board searching for permanent CEO.","Berg's annual base salary set at $700,000; target bonus remains 50% of base salary.","Oliver O'Connor appointed to Board and Nominating & Corporate Governance Committee.","O'Connor brings 30+ years in government, policy, and pharma; currently CEO of Irish Pharmaceutical Healthcare Association.","Board expands to 8 directors, all independent, including one Irish-domiciled member."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328604,"accession_number":"0001193125-23-086943","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-03-31T23:59:59+00:00","items":["5.02","7.01"],"status":"ready","headline":"CEO Karim Mikhail resigns effective immediately; company disputes severance claim","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karim Mikhail resigned as President and CEO effective March 27, 2023.","Mikhail asserts entitlement to severance; company disagrees and intends to dispute.","Board appoints Odysseas D. Kostas as chairperson.","Company is in the process of identifying a permanent replacement for CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328603,"accession_number":"0001193125-23-061610","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-03-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Amarin announces resignation of seven independent directors after Sarissa proxy win","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Seven independent non-Sarissa board members resigned effective March 6, 2023.","Resignations were to avoid further proxy contests and allow Sarissa immediate control.","Departing directors include Adam Berger, Erin Enright, Geraldine Murphy, Kristine Peterson, Dr. Murray Stewart, Jan van Heek, and Alfonso Zulueta.","Resignations not due to any disagreement with company operations, policies, or practices.","Sarissa slate won at 2023 Special Meeting of Shareholders, prompting board change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328602,"accession_number":"0001193125-23-057381","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-03-02T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Amarin shareholders vote to remove director Per Wold-Olsen and elect seven new directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Removed director Per Wold-Olsen with 171.5M votes for, 60.6M against, effective immediately.","Elected Patrice Bonfiglio, Paul Cohen, Mark DiPaolo, Keith L. Horn, Odysseas Kostas, Louis Sterling III, Diane E. Sullivan as directors.","Approved removal of any director appointed between Jan 10 and Feb 28, 2023, with 177.4M votes for.","Quorum of ~58% of outstanding shares present; all resolutions passed by poll."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328601,"accession_number":"0000950170-23-005329","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-03-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Amarin Q4 2022 net income $0.9M; revenue down 38% YoY; positive free cash flow $4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 net product revenue $89.5M, down 38% YoY; U.S. revenue stabilized at $88.0M vs $87.9M in Q3.","GAAP net income $0.9M ($0.00 EPS); non-GAAP adjusted net income $7.3M ($0.02 EPS).","Positive free cash flow of $4M in Q4; cost savings program on track to exceed $100M target.","European expansion: VAZKEPA launched in 5 markets, pricing negotiations in 5 more; peak revenue potential $1B+ in Europe.","International: 6 regulatory approvals in 2022, plus New Zealand in Jan 2023; license agreement with CSL Seqirus for Australia/NZ."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":369193000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328600,"accession_number":"0001193125-23-042135","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Amarin refutes Sarissa's claim that it refused to accept blue proxy cards","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sarissa claimed Amarin did not intend to accept blue proxy cards; Amarin says this is categorically false.","By 9:00 a.m. ET on Feb 15, Amarin's counsel told registrar to accept blue cards; registrar confirmed acceptance by 9:30 a.m.","Sarissa issued its press release with false claims seven hours after the confusion was resolved.","Email evidence shows registrar asked Amarin about the blue cards and was told to accept them.","Amarin urges SEC to require Sarissa to correct its materially misleading disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328599,"accession_number":"0001193125-23-005718","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Amarin reports preliminary Q4 revenue $88-90M, FY 2022 rev $367-369M, cash $310M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 total net revenue estimated $88-90M; full-year 2022 revenue $367-369M (preliminary, unaudited).","Cash and investments at year-end ~$310M; positive Q4 cash flow of ~$4M.","U.S. VASCEPA business achieved fourth consecutive quarter of revenue stabilization amid generic competition.","Secured positive pricing/reimbursement decisions in five European markets during 2022; negotiations ongoing in Spain, Italy, France, Norway, Netherlands.","2023 priorities: accelerate European revenues, maintain U.S. profitability, progress international filings (up to 9 countries), advance FDC program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":369193000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328598,"accession_number":"0001193125-23-005176","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K","filed_at":"2023-01-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Amarin appoints Murray Stewart to Board; 75% of directors new in last 12 months","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Murray Stewart, DM FRCP, appointed to Amarin Board effective January 9, 2023.","Stewart brings 30+ years cardiometabolic experience; formerly CMO at GSK and Rhythm Pharmaceuticals.","Approximately 75% of independent directors are new, with six appointments over the past 12 months.","Stewart will serve until 2023 AGM and then stand for election by shareholders.","He will receive standard non-employee director equity awards and annual fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":328596,"accession_number":"0001193125-23-002508","cik":897448,"company_name":"AMARIN CORP PLCUK","ticker":"AMRN","form_type":"8-K/A","filed_at":"2023-01-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Amarin appoints Berger and Murphy to Nominating and Corporate Governance Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Adam Berger and Geraldine Murphy appointed to Nominating and Corporate Governance Committee effective Jan 5, 2023.","Berger named Chair; both join existing member Kristine Peterson.","Appointments follow retirement of Lars Ekman and Patrick J. O'Sullivan from committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":300010144.0,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-01-05T23:59:59+00:00|328596"}